NCT06921317 - GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

February 28, 2027

Conditions

Primary Open-Angle Glaucoma (POAG)

Interventions

DRUG

GVB-2001-high dose

GVB-2001 is a self-complementary adeno-associated viral vector (scAAV) injection to deliver human dnRhoA gene to trabecular meshwork cells in patients with primary open angle glaucoma. A single dose of high dose GVB-2001 will be injected intracamerally to the target interventional eye.

DRUG

GVB-2001-low dose

GVB-2001 is a self-complementary adeno-associated viral vector (scAAV) injection to deliver human dnRhoA gene to trabecular meshwork cells in patients with primary open angle glaucoma. A single dose of low dose GVB-2001 will be injected intracamerally to the target interventional eye.

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou